PHASE-I STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND SLEEP PROMOTING ACTIVITY OF Neu-P11, A NOVEL PUTATIVE INSOMNIA DRUG IN HEALTHY HUMANS

被引：0
|
作者：
Yalkinoglu, Oe [1 ]
Zisapel, N. [4 ]
Nir, T. [4 ]
Piechatzek, R. [1 ]
Schorr-Neufing, U. [1 ]
Bitterlich, N. [1 ]
Oertel, R. [3 ]
Allgaier, C. [2 ]
Kluge, A. [1 ]
Laudon, M. [4 ]
机构：
[1] ABX CRO Adv Pharmaceut Serv Forsch GmbH, Dresden, Germany
[2] ACA Pharma Concept GmbH, Leipzig, Germany
[3] Tech Univ, Inst Clin Pharmacol, Fac Med, Dresden, Germany
[4] Neurim Pharmaceut Ltd, Tel Aviv, Israel
来源：
SLEEP | 2010年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
0656
引用
收藏
页码：A220 / A220
页数：1
相关论文
共 35 条
  • [31] Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects
    Liu, Xiaoxue
    Xue, Ling
    Zhang, Hua
    Xu, Qingqing
    Zhang, Shichao
    Ma, Sheng
    Ding, Xiaoliang
    Liu, Linsheng
    Dong, Ji
    Qian, Lifang
    Xia, Wen
    Jiang, Kun
    Huang, Chenrong
    Miao, Liyan
    CLINICAL DRUG INVESTIGATION, 2020, 40 (06) : 555 - 566
  • [32] Phase I, First-in-Human, Single and Multiple Ascending Dose- and Food-Effect Studies to Assess the Safety, Tolerability and Pharmacokinetics of a Novel Anti-hepatitis B Virus Drug, Bentysrepinine (Y101), in Healthy Chinese Subjects
    Xiaoxue Liu
    Ling Xue
    Hua Zhang
    Qingqing Xu
    Shichao Zhang
    Sheng Ma
    Xiaoliang Ding
    Linsheng Liu
    Ji Dong
    Lifang Qian
    Wen Xia
    Kun Jiang
    Chenrong Huang
    Liyan Miao
    Clinical Drug Investigation, 2020, 40 : 555 - 566
  • [33] Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study
    Xu, Jia
    Zhang, Hong
    Chen, Hong
    Zhu, Xiaoxue
    Jia, Haiyan
    Xu, Zhongnan
    Huo, Dandan
    Zhang, Hong
    Li, Cuiyun
    Ding, Yanhua
    ANNALS OF MEDICINE, 2023, 55 (02)
  • [34] RESULTS OF A PHASE 1, 4-PERIOD CROSSOVER, PLACEBO-CONTROLLED, RANDOMIZED, SINGLE DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF TAK-925, A NOVEL OREXIN 2 RECEPTOR AGONIST, IN SLEEP-DEPRIVED HEALTHY ADULTS, UTILIZING MODAFINIL AS AN ACTIVE COMPARATOR
    Evans, R.
    Hazel, J.
    Faessel, H.
    Wu, J.
    Hang, Y.
    Alexander, R.
    Rosen, L.
    Hartman, D.
    SLEEP MEDICINE, 2019, 64 : S106 - S106
  • [35] A phase I, open-label, multicenter, first-in-human study of the safety, tolerability, pharmacokinetics, and antitumor activity of TPX-0022, a novel MET/CSF1R/SRC inhibitor, in patients with advanced solid tumors harboring genetic alterations in MET.
    Hong, David S.
    Sen, Shiraj
    Park, Haeseong
    Heist, Rebecca Suk
    Gadgeel, Shirish M.
    Zimmerman, Zachary Franklin
    Bazhenova, Lyudmila
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
1234